• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
ESPR

ESPR

Esperion Therapeutics, Inc.

NASDAQHealthcareBiotechnologyUS

USD3.14

+0.00 (+0.00%)

Rating:C-

Company Profile

CEO

Sheldon L. Koenig

IPO Date

2013-06-26

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$3.13

Prev. Close

$3.14

Day Low

$3.13

Day High

$3.14

52W Low

$0.95

52W High

$4.18

Market Cap

$0.65B

Volume

19.62M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBearish

Articles

10

Avg Positive

14.8%

Avg Negative

37.4%

Avg Neutral

47.9%

News Feed

Esperion to Participate in Upcoming Virtual Investor Conference

GlobeNewsWire·8/26/2021·↑ positive

Esperion: Hunting Big Game In The Danger Zone

Seeking Alpha·8/4/2021·↓ negative

Esperion Therapeutics, Inc. (ESPR) CEO Sheldon Koenig on Q2 2021 Results - Earnings Call Transcript

Seeking Alpha·8/3/2021·↓ negative

Esperion Therapeutics (ESPR) Reports Q2 Loss, Misses Revenue Estimates

Zacks Investment Research·8/3/2021·↑ positive

Recap: Esperion Therapeutics Q2 Earnings

Benzinga·8/3/2021·↓ negative

Esperion Shorts Have Cleaned Up

GuruFocus·7/1/2021·↓ negative

Why Is Esperion Therapeutics (ESPR) Up 6.4% Since Last Earnings Report?

Zacks Investment Research·6/3/2021·↓ negative

ESPERION Appoints Sheldon Koenig as President and CEO

GlobeNewsWire·5/17/2021·↑ positive

Simulation Model based on Pooled Phase 3 Data Demonstrating NEXLETOL® (bempedoic acid) Tablet's Potential to Lower Absolute Cardiovascular Event Risk Presented at ACC.21

GlobeNewsWire·5/15/2021·↑ positive

Esperion: A Change In Plans After A Disappointing Q1 Earnings

Seeking Alpha·5/6/2021·↓ negative